- CDC officials awarded $4.9 million to researchers at Brown University and their case university to study COVID vaccine effectiveness in seniors
- The team will study 800 to 1,200 nursing home residents who have received a vaccine, including a group that will receive a booster.
- Researchers will analyze residents’ immune response and overall health to see if antibody levels change over time
- Previous studies have suggested that elderly people see a dramatic drop in antibody levels after six months.
Brown University has been awarded 4.9 million by the Centers for Disease Control and Prevention (CDC) to study the effectiveness of vaccines among seniors.
The two-year project will look at nursing home residents after getting a thorough vaccination or booster shot.
Nursing home residents were among the first to have the Covid vaccine provided to them in December 2020, as the facilities quickly became a place of death and despair in the pandemic.
But officials worry that some early adopters of the vaccine may not be as safe as they were after receiving the shot.
CDC officials have awarded $4.9 million to researchers from Brown University and their case university to study COVID vaccine effectiveness in seniors. Image: CVS pharmacist William Hallock gives the Pfizer-BioNtech COVID vaccine to Kendall-Crossland Communities staff member Georgie Stoker in January 2021 in Kennett, Pennsylvania
Co-principal investigator Dr Stephen Gravenstein, Professor of Geriatric Medicine at Brown, said: “Given the increasing cases of delta variants, we need to know as soon as possible who needs a vaccine booster shot and when they need it.” . Statement.
This information on how specific immunity to SARS-CoV-2 infection decreases with age, disease and long-term care residents is important for developing a booster strategy based on real-time data in this population. is critically important.’
Researchers will look at 800 to 1,200 nursing home residents who have received a COVID vaccine, including a group that will receive a booster.
The team will look at the residents’ immune response and overall health to see if antibody levels change over time.
The data will be shared with the CDC every six months.
study is previously shown Older people develop a weaker immune response to vaccines than younger people,
This is because the immune system tends to break down with age, a phenomenon known as immunosenescence.
what’s more, A large number of serious success cases – in which a fully vaccinated person contracts the virus – are among senior citizens.
The new research will follow previous studies by Gravenstein and Dr. David Kennedy, who are professors in the division of infectious diseases and HIV medicine at Case Western Reserve University.
Their pre-print study, published in August, looked at blood samples from 120 nursing home residents and 92 health care workers who were given the Pfizer-BioNTech vaccine.
Over a six-month period, antibody levels, including neutralizing antibodies, were found to drop by more than 84 percent.
Additionally, 70 percent of nursing home residents had levels down or barely detectable after six months, while 16 percent saw the same thing after two weeks.
Another study published by Gravenstein, Kennedy AMD MD Elizabeth White, assistant professor of health services, policy and practice, also found that seniors established a weaker immune response.
“In addition to the obvious value of who and when to promote against SARS-CoV-2 infection, we have also made considerable progress in how to efficiently recruit and immunocompromise a long-term care population,” Gravenstein said in a statement. Have done something new.
‘This methodological advancement takes advantage of Brown’s strength in the intersection between biology, aging and public health research.’